A First Generic Patch

FDA approved the first generic patch equivalent to Climara Pro, a once-weekly hormone therapy for women with an intact uterus.

Two Hormones, One Patch

The patch delivers estradiol, an estrogen, and levonorgestrel, a progestogen, through the skin once each week.

Approved Menopause Use

For women with an intact uterus, FDA approved it to treat moderate to severe vasomotor symptoms due to menopause.

Osteoporosis Prevention

Its other approved use is preventing osteoporosis after menopause; the announcement does not say it treats established osteoporosis.

Why Include Progestogen?

FDA says the progestogen component reduces the risk of endometrial hyperplasia, an overgrowth of the uterine lining that can occur with estrogen

Safety Restrictions Remain

Contraindications include undiagnosed abnormal bleeding, certain cancers and blood clots, liver disease, hypersensitivity, and some blood-clotting disorders.

Price And Launch Unknown

FDA gave no price or pharmacy launch date, and directed readers to the manufacturer for availability information.